News
GW Pharma begins recruitment for US-based Sativex trial
GW Pharmaceuticals has initiated the first US phase III clinical trial studying nabiximols for multiple sclerosis (MS) associated spasticity.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
GW Pharmaceuticals has initiated the first US phase III clinical trial studying nabiximols for multiple sclerosis (MS) associated spasticity.